Lili Nsongo's questions to Schrodinger Inc (SDGR) leadership • Q2 2025
Question
Lili Nsongo, on behalf of Mani Faroohar at Leerink Partners, questioned the adoption and growth expectations for the new predictive toxicology feature and asked to quantify the potential for increased usage among existing customers.
Answer
CEO Ramy Farid highlighted that the recently launched beta version of the predictive toxicology feature is seeing significant excitement and demand, aligning with the FDA's push to reduce animal testing. CFO Richie Jain added that there is substantial room for growth within existing customers, with a key strategy being the migration of smaller and medium-tier accounts to larger contracts.